Avadel Pharmaceuticals (AVDL) Change in Account Payables: 2009-2024
Historic Change in Account Payables for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to -$4.1 million.
- Avadel Pharmaceuticals' Change in Account Payables rose 92.22% to $8.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$3.1 million, marking a year-over-year decrease of 173.44%. This contributed to the annual value of -$4.1 million for FY2024, which is 364.92% down from last year.
- According to the latest figures from FY2024, Avadel Pharmaceuticals' Change in Account Payables is -$4.1 million, which was down 364.92% from $1.5 million recorded in FY2023.
- In the past 5 years, Avadel Pharmaceuticals' Change in Account Payables ranged from a high of $4.2 million in FY2021 and a low of -$4.1 million during FY2024.
- Its 3-year average for Change in Account Payables is -$1.9 million, with a median of -$3.1 million in 2022.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Change in Account Payables soared by 251.79% in 2021, and later crashed by 364.92% in 2024.
- Avadel Pharmaceuticals' Change in Account Payables (MRY) stood at -$2.8 million in 2020, then surged by 251.79% to $4.2 million in 2021, then tumbled by 173.44% to -$3.1 million in 2022, then soared by 149.71% to $1.5 million in 2023, then tumbled by 364.92% to -$4.1 million in 2024.
- Its Change in Account Payables stands at -$4.1 million for FY2024, versus $1.5 million for FY2023 and -$3.1 million for FY2022.